An epidemiological study on the factors including genetic polymorphism influencing <scp>ALT</scp> ><scp>30 U</scp>/L and liver fibrosis progression in metabolic dysfunction‐associated steatotic liver disease among the general population
An individualized treatment approach is warranted for patients with MASLD due to the influence of various factors on its progression, including genetic factors and lifestyle diseases.
Authors
- Tatsuya Mikami (ORCID: https://orcid.org/0000-0002-6657-6446)
- Kaori Sawada
- Shigeyuki Nakaji (ORCID: https://orcid.org/0000-0002-4190-5151)
- Kenta Yoshida (ORCID: https://orcid.org/0000-0002-3897-5546)
- Shinsaku Fukuda (ORCID: https://orcid.org/0000-0002-4788-1816)
- Takafumi Sasada
- Chikara Iino (ORCID: https://orcid.org/0000-0001-6844-4415)
- Hirotake Sakuraba (ORCID: https://orcid.org/0000-0002-6075-1282)
- Satoshi Sato (ORCID: https://orcid.org/0000-0001-5569-7093)
- K. Furusawa
- Go Soma (ORCID: https://orcid.org/0000-0002-9960-9937)
Institutions
- Hirosaki University (JP)
Publication Details
- Journal
- JGH Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/jgh3.70043
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Science and Technology Agency